Bloomberg Law
Sept. 30, 2022, 7:47 PM

Siga’s Tpoxx Study Enrollment Slows as Monkeypox Cases Wane

Jeannie Baumann
Jeannie Baumann

Enrollment in Siga Technologies Inc.’s monkeypox treatment trial is facing a slowdown as a decline in cases makes it more difficult to recruit volunteers.

The National Institutes of Health opened its monkeypox treatment study, known as the STOMP trial, about three weeks ago to evaluate the safety and efficacy of Tpoxx. The Food and Drug Administration approved the antiviral for smallpox in 2018 and the trial will bring crucial answers about how well the drug works in humans for a close cousin of the smallpox virus.

New cases have decelerated week over week, with 25,600 cases identified in ...